- Medicine Name: Empaveli
- Generic Name: Pegcetacoplan
- Dosage Form & Strength: Injection: 1,080 mg/20 mL (54 mg/mL) in a single-dose vial
- Manufactured By: Apellis Pharmaceuticals, Inc.
Empaveli is a complement inhibitor used for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Recommended Dosage: Patients should be vaccinated against encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B at least a couple of weeks before initiating Empaveli 1,080 mg/20 mL (54 mg/mL) therapy as per the current ACIP guidelines.
Two weeks of antibacterial drug prophylaxis should be provided to patients if Pegcetacoplan must be initiated promptly and vaccines are given less than 2 weeks prior to starting therapy with Empaveli.
The recommended dose is 1,080 mg administered by subcutaneous infusion twice weekly via a commercially available infusion pump with a reservoir of at least 20 mL.
Administer this medication as promptly as possible after a missed/skipped dose. Resume the regular dosing schedule after administration of the skipped/missed dose.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.